低剂量氯胺酮与吗啡治疗急诊科急性疼痛:15项随机对照试验的Meta分析
该Meta分析基于Cochrane方法,纳入15项随机对照试验、共1768例急诊科成年急性疼痛患者,比较低剂量氯胺酮与吗啡的镇痛效果与安全性。主要结局为数字评分量表(NRS)和视觉模拟量表(VAS)。结果显示氯胺酮组30分钟NRS低于吗啡组(MD -0.77,95%CI -0.93至-0.61;p<0.00001),吗啡组120分钟镇痛效果更好(MD 0.33,95%CI 0.15至0.51;p=0.0003);氯胺酮组15分钟疼痛完全缓解更优(RR 3.18,95%CI 1.75至5.78;p=0.0001),需干预的不良事件发生率更低(RR 0.34,95%CI 0.18至0.66;p=0.001)。亚组分析显示静脉氯胺酮30分钟VAS低于吗啡组,而鼻内氯胺酮30分钟VAS镇痛效果劣于吗啡。作者认为氯胺酮早期镇痛更好、吗啡作用更持久,静脉给药比鼻内给药更有效。
要点
- 15项RCT、1768例急诊成年急性疼痛患者:低剂量氯胺酮组30分钟NRS低于吗啡组(MD -0.77,95%CI -0.93至-0.61;p<0.00001)。
- 吗啡组120分钟镇痛效果更好(MD 0.33,95%CI 0.15至0.51;p=0.0003),提示吗啡作用更持久。
- 氯胺酮组15分钟疼痛完全缓解优于吗啡组(RR 3.18,95%CI 1.75至5.78;p=0.0001)。
- 氯胺酮组需干预的不良事件发生率低于吗啡组(RR 0.34,95%CI 0.18至0.66;p=0.001)。
- 亚组分析:静脉氯胺酮30分钟VAS低于吗啡组,而鼻内氯胺酮30分钟VAS镇痛效果劣于吗啡,静脉给药更有效。
适用人群与场景
- 急诊科成年急性疼痛患者,试验组接受低剂量氯胺酮、对照组接受吗啡。
研究设计与关键结果
- 研究类型为Meta分析,基于Cochrane方法,仅纳入随机对照试验,共纳入15项RCT、1768例患者,使用Review Manager数据库分析。
- 主要结局:氯胺酮组30分钟NRS低于吗啡组(MD -0.77,95%CI -0.93至-0.61;p<0.00001);吗啡组120分钟镇痛效果更好(MD 0.33,95%CI 0.15至0.51;p=0.0003)。
- 氯胺酮组15分钟疼痛完全缓解优于吗啡组(RR 3.18,95%CI 1.75至5.78;p=0.0001)。
- 氯胺酮组需干预的不良事件发生率低于吗啡组(RR 0.34,95%CI 0.18至0.66;p=0.001)。
- 亚组分析:静脉氯胺酮30分钟VAS低于吗啡组;鼻内氯胺酮30分钟VAS镇痛效果劣于吗啡。
证据类型、等级与局限
- 证据类型:基于15项随机对照试验的Meta分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为氯胺酮在治疗后早期镇痛效果更好,而吗啡维持更持久的效果。
- 作者认为与吗啡相比,氯胺酮需干预的不良事件发生率更低。
- 亚组分析结果提示静脉给予氯胺酮比鼻内给药更有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the effectiveness and safety of ketamine and morphine in adult patients with acute pain in emergency department (ED) by using a meta-analysis method.
METHODS: This study was based on the Cochrane methodology for conducting a meta-analysis. Only randomized controlled trials (RCTs) were eligible for this study, with an experimental group that received low-dose ketamine and a control group that received morphine. The participants were adults who had acute pain in the ED. The primary outcome measures were the numeric rating scale (NRS) and visual analog scale (VAS). The secondary outcome measures were the complete resolution of pain, NRS reduction ≥3 points, NRS reduction ≥50% or 60%, change of NRS score, change of VAS score, rescue analgesia, satisfaction and adverse events. Subgroup analysis was performed for studies with intravenous and intranasal administration of ketamine. The Review Manager Database was used to analyze the included studies.
RESULTS: 15 RCTs involving 1768 patients were included. The ketamine group had lower NRS scores than morphine group at 30 min (MD, -0.77 [95% CI, -0.93 to -0.61]; p < 0.00001), while the morphine had better analgesic effects at 120 min after treatment (MD, 0.33 [95% CI, 0.15 to 051]; p = 0.0003). The subjects of complete resolution of pain in the ketamine group performed better than those in the morphine group at 15 min (RR 3.18, 95% CI 1.75 to 5.78; p = 0.0001). Compared with the morphine group, the ketamine group had a lower incidence of adverse events requiring intervention (RR, 0.34 [95% CI, 0.18 to 0.66]; p = 0.001). Subgroup analysis of intravenous ketamine showed that ketamine had lower VAS score than the morphine group at 30 min. However, also on the 30-min VAS score, intranasal ketamine analgesia was less effective than morphine.
CONCLUSIONS: Ketamine had better analgesic effects in the early stages after treatment, while morphine maintained more durable effects. Compared with morphine, ketamine had a lower incidence of adverse events requiring intervention. The results of subgroup analysis showed that intravenous administration of ketamine was more effective than intranasal administration.
参考来源
- Guo J, Zhao F, Bian J, et al. Low-dose ketamine versus morphine in the treatment of acute pain in the emergency department: A meta-analysis of 15 randomized controlled trials. Am J Emerg Med. 2023. PMID: 38071883. doi:10.1016/j.ajem.2023.11.056
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。